½ÃÀ庸°í¼­
»óǰÄÚµå
1520504

Ç÷ÇൿÅ ¸ð´ÏÅ͸µ ½ÃÀå º¸°í¼­ : Á¦Ç°, ¸ð´ÏÅ͸µ, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Hemodynamic Monitoring Market Report by Product, Monitoring, End-User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 149 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Ç÷ÇൿÅ ¸ð´ÏÅ͸µ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 11¾ï 5,000¸¸ ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº ½ÃÀåÀÌ 2032³â±îÁö 16¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2032³â 4.2%ÀÇ ¼ºÀå·ü(CAGR)À» º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù.

Ç÷ÇൿÅ ¸ð´ÏÅ͸µÀº ½ÉÀå, Á¤¸Æ, µ¿¸Æ¿¡ ÀÛ¿ëÇÏ´Â Ç÷·ù¿Í ¾Ð·ÂÀ» ÃøÁ¤ÇÏ´Â °úÁ¤À» ¸»ÇÕ´Ï´Ù. Ç÷ÇൿÅ ÆÄ¶ó¹ÌÅÍ¿Í »ê¼Ò °ø±ÞÀ» Æò°¡Çϰí ÃÖÀûÈ­ÇÏ¿© ´Ù¾çÇÑ ½ÉÆó ÁúȯÀÇ Áø´Ü ¹× Ä¡·á, ÁßÁõ ȯÀÚÀÇ °á°ú¸¦ °³¼±ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ¼ö³â°£ Ç÷ÇൿÅ ¸ð´ÏÅ͸µÀº ½É¹ÚÃâ·®(CO)ÀÇ ±âº»ÀûÀÎ ÃßÀû¿¡¼­ Ç÷¾Ð, Ç÷¾×·®, ü¾× ±ÕÇü°ú °°Àº ´Ù¾çÇÑ º¯¼ö¿¡ ´ëÇÑ Á¤º¸¸¦ Á¦°øÇϴ ÷´Ü Àåºñ·Î ¹ßÀüÇØ ¿Ô½À´Ï´Ù.

¼ö³â µ¿¾È ½ÉÀå ±â´É Àå¾Ö¸¦ ¾Î°í ÀÖ´Â »ç¶÷µéÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, ±× °á°ú Ç÷ÇൿÅÂÀÌ ºÒ¾ÈÁ¤ÇØÁ® °á±¹ Àå±â ºÎÀüÀ¸·Î À̾îÁý´Ï´Ù. ±× °á°ú Àü ¼¼°è¿¡¼­ Ç÷ÇൿÅ ¸ð´ÏÅ͸µ¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çß½À´Ï´Ù. ÀÌ¿¡ µû¶ó ºñħ½ÀÀû µ¿¸Æ¾Ð ÆÄÇü ºÐ¼®À» ÅëÇØ ¾òÀ» ¼ö ÀÖ´Â º¸´Ù Çõ½ÅÀûÀÌ°í º¸Á¤µÇÁö ¾ÊÀº ºñħ½ÀÀû CO ÃøÁ¤ÀÇ µµÀÔµµ ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯ÀÚÀÇ ¿¹Èĸ¦ °³¼±Çϰí ÁßÁõ ȯÀÚÀÇ Á¶Á÷ Àú»ê¼ÒÁõ, ¼îÅ©, ´Ù¹ß¼º Àå±â ºÎÀüÀ» ¹æÁöÇϱâ À§ÇØ ÀÇ·á°è Àü¹Ý¿¡¼­ Ç÷ÇൿÅ ¸ð´ÏÅ͸µÀÇ »ç¿ëÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±¤¹üÀ§ÇÑ ¿¬±¸°³¹ß(R&D) Ȱµ¿Àº ¶Ç ´Ù¸¥ ÁÖ¿ä ¼ºÀå µ¿·ÂÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Á¦Á¶¾÷üµéÀº º¸´Ù °£ÆíÇϰí Àú·ÅÇÑ °¡°ÝÀÇ Àúħ½ÀÀû ¹× ºñħ½ÀÀû Ç÷ÇൿÅ ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀ» °³¹ßÇÏ¿© º¸´Ù Á¤È®ÇÑ °á°ú¸¦ Á¦°øÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù. ÀÌ ¿Ü¿¡µµ Á¤ºÎ ¹× ¹Î°£ ºÎ¹®ÀÇ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í ±â¼ú ¹ßÀüÀº ÇâÈÄ ¼ö³â°£ ½ÃÀå Àü¸ÁÀ» ´õ¿í ¹à°ÔÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ º¸°í¼­¿¡¼­ ´Ù·é ÁÖ¿ä Áú¹®

  • ¼¼°è Ç÷ÇൿÅ ¸ð´ÏÅ͸µ ½ÃÀåÀº Áö±Ý±îÁö ¾î¶»°Ô ¼ºÀåÇØ¿Ô°í, ¾ÕÀ¸·Î ¾î¶»°Ô ¹ßÀüÇÒ °ÍÀΰ¡?
  • ÁÖ¿ä Áö¿ª ½ÃÀåÀº?
  • COVID-19°¡ ¼¼°è Ç÷ÇൿÅ ¸ð´ÏÅ͸µ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • Á¦Ç°º° ½ÃÀå ºÐ¼®Àº?
  • ¸ð´ÏÅ͸µº° ½ÃÀå ºÐ¼®Àº?
  • »ê¾÷ ¹ë·ùüÀÎÀÇ ´Ù¾çÇÑ ´Ü°è´Â?
  • ¾÷°èÀÇ ÁÖ¿ä ÃËÁø¿äÀΰú °úÁ¦´Â?
  • ¼¼°è Ç÷ÇൿÅ ¸ð´ÏÅ͸µ »ê¾÷ÀÇ ±¸Á¶¿Í ÁÖ¿ä ±â¾÷Àº?
  • ¾÷°èÀÇ °æÀïÀº ¾î´À Á¤µµÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • º¸ÅÒ¾÷ Á¢±Ù
    • Åé´Ù¿î Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå °³¿ä

Á¦4Àå ¼­·Ð

  • °³¿ä
  • ÁÖ¿ä ¾÷°è µ¿Çâ

Á¦5Àå ¼¼°èÀÇ Ç÷Çà µ¿Å ¸ð´ÏÅ͸µ ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : Á¦Ç°º°

  • ÀÏȸ¿ë
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ¸ð´ÏÅÍ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦7Àå ½ÃÀå ³»¿ª : ¸ð´ÏÅ͸µ

  • ħ½ÀÀû ¸ð´ÏÅ͸µ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Àúħ½À ¸ð´ÏÅ͸µ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ºñħ½ÀÀû ¸ð´ÏÅ͸µ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • Áø·á¼Ò ¹× ¿Ü·¡ Áø·á ¼¾ÅÍ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ȨÄɾî ȯ°æ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø
  • ±âŸ
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ¿¹Ãø

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ¹ÙÀ̾îÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀïÀÇ Á¤µµ
  • ½Å±Ô ÁøÃâ¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °æÀï ±¸µµ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ÀÇ °³¿ä
    • Edwards Lifesciences Corporation
    • Lidco Group PLC
    • Deltex Medical Group PLC
    • Pulsion Medical Systems SE
    • GE Healthcare
    • Osypka Medical GmbH
    • Tensys Medical
    • Teleflex Incorporated
    • ICU Medical Inc.
    • Argon Medical
    • Schwarzer Cardiotek GmbH
KSA 24.07.30

The global hemodynamic monitoring market size reached US$ 1.15 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 1.68 Billion by 2032, exhibiting a growth rate (CAGR) of 4.2% during 2024-2032.

Hemodynamic monitoring refers to the process of measuring the blood flow and pressure exerted in the heart, veins and arteries. It enables the assessment and optimization of hemodynamic parameters and oxygen delivery, which helps in diagnosing and treating various cardiopulmonary conditions and improving outcomes in critically ill patients. Over the years, hemodynamic monitoring has evolved from basic tracking of cardiac output (CO) to advanced devices that provide information about a wide array of variables, like blood pressure, blood volume and fluid balance.

Over the years, there has been a rise in the number of people suffering from cardiac dysfunction, which results in hemodynamic instability, thus ultimately leading to organ failure. Consequently, the demand for hemodynamic monitoring has significantly increased across the globe. In line with this, the introduction of more innovative, uncalibrated and non-invasive CO measurements obtained through the analysis of a non-invasive arterial pressure waveform is also contributing to the market growth. Furthermore, hemodynamic monitoring is being increasingly used across the healthcare sector to improve patient outcome and combat tissue hypoxia, shock and multiorgan failure in critically ill patients. Extensive research and development (R&D) activities act as another major growth-inducing factor. Manufacturers are undertaking initiatives for the development of simpler minimally- and non-invasive hemodynamic monitoring systems at affordable prices, which will offer more precise results. Other factors, rising healthcare expenditure by both government and private sectors and technological advancements, are further expected to create a positive outlook for the market in the coming years.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemodynamic monitoring market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product, monitoring and end-user.

Breakup by Product:

Disposables

Monitors

Others

Breakup by Monitoring:

Invasive Monitoring

Minimally Invasive Monitoring

Noninvasive Monitoring

Breakup by End-User:

Hospitals

Clinics and Ambulatory Care Centers

Home Care Settings

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Edwards Lifesciences Corporation, Lidco Group PLC, Deltex Medical Group PLC, Pulsion Medical Systems SE, GE Healthcare, Osypka Medical GmbH, Tensys Medical, Teleflex Incorporated, ICU Medical Inc., Argon Medical, Schwarzer Cardiotek GmbH, etc.

Key Questions Answered in This Report:

  • How has the global hemodynamic monitoring market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global hemodynamic monitoring market?
  • What is the breakup of the market based on the product?
  • What is the breakup of the market based on the monitoring?
  • What is the breakup of the market based on the end-user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global hemodynamic monitoring industry and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hemodynamic Monitoring Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product

  • 6.1 Disposables
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Monitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Monitoring

  • 7.1 Invasive Monitoring
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Minimally Invasive Monitoring
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Noninvasive Monitoring
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by End-User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics and Ambulatory Care Centers
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Home Care Settings
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Edwards Lifesciences Corporation
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 Lidco Group PLC
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
    • 13.3.3 Deltex Medical Group PLC
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
    • 13.3.4 Pulsion Medical Systems SE
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
    • 13.3.5 GE Healthcare
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
    • 13.3.6 Osypka Medical GmbH
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
    • 13.3.7 Tensys Medical
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Teleflex Incorporated
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
    • 13.3.9 ICU Medical Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
    • 13.3.10 Argon Medical
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
    • 13.3.11 Schwarzer Cardiotek GmbH
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦